Dynavax Technologies Corporation (NASDAQ: DVAX) Stock Information | RedChip

Dynavax Technologies Corporation (NASDAQ: DVAX)


$12.8200
-0.0200 ( 0% ) 332.2K

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Market Data


Open


$12.8200

Previous close


$12.8400

Volume


332.2K

Market cap


$1.69B

Day range


$12.7250 - $12.8450

52 week range


$9.7400 - $15.0100

SEC Filings


Form Type Description Pages Date
8-k 8K-related 14 Nov 12, 2024
10-q Quarterly Reports 78 Nov 07, 2024
8-k 8K-related 15 Nov 07, 2024
8-k 8K-related 16 Oct 29, 2024
3 Insider transactions 1 Oct 24, 2024
10-q Quarterly Reports 75 Aug 06, 2024
8-k 8K-related 13 Aug 06, 2024
8-k 8K-related 11 Aug 02, 2024
4 Insider transactions 1 Jun 03, 2024
4 Insider transactions 1 May 28, 2024

Latest News